WorldPharmaNews
Search ...
Home
Business
Research
Events
Regulatory
GSK - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer.
www.gsk.com
GlaxoSmithKline RSS Channel
Filters
Display #
5
10
15
20
25
30
50
100
All
Filter
List of articles in category GlaxoSmithKline
Title
Published Date
Sanofi and GSK initiate new Phase 2 study of their adjuvanted recombinant protein-based COVID-19 vaccine candidate
24 February 2021
GSK and Vir Biotechnology expand coronavirus collaboration to advance new therapeutics for influenza and other respiratory viruses
19 February 2021
GSK and CureVac to develop next generation mRNA COVID-19 vaccines
04 February 2021
Vir Biotechnology and GSK announce NHS-supported AGILE study to evaluate VIR-7832 in the early treatment of COVID-19
15 January 2021
Vir Biotechnology and GSK announce start of NIH-sponsored ACTIV-3 trial evaluating VIR-7831 in hospitalised adults with COVID-19
17 December 2020
Sanofi and GSK announce a delay in their adjuvanted recombinant protein-based COVID-19 vaccine programme to improve immune response in the elderly
11 December 2020
Medicago and GSK announce start of Phase 2/3 clinical trials of adjuvanted COVID-19 vaccine candidate
12 November 2020
Vir Biotechnology and GSK announce global expansion to Phase 3 of COMET-ICE study evaluating VIR-7831 for the treatment of COVID-19
07 October 2020
Sanofi and GSK sign agreements with the Government of Canada to supply up to 72 million doses of adjuvanted COVID-19 vaccine
23 September 2020
Vir Biotechnology and GSK start phase 2/3 study of COVID-19 antibody treatment
31 August 2020
Start
Prev
1
2
3
4
5
6
7
8
9
10
Next
End
Business & Industry
Novartis signs initial agreement with CureVac to manufacture COVID-19 vaccine candidate
AstraZeneca advances mass global rollout of COVID-19 vaccine through COVAX
Abbott researchers find rare group of people with controlled HIV who could be a key to unlocking cure
Pfizer and BioNTech initiate a study as part of broad development plan to evaluate COVID-19 booster and new vaccine variants
Sanofi and GSK initiate new Phase 2 study of their adjuvanted recombinant protein-based COVID-19 vaccine candidate
Research & Development
New evidence COVID-19 antibodies, vaccines less effective against variants
Vaccine development software shows promise in influenza effort, could help defeat coronavirus
Researchers discover SARS-CoV-2 inhibitors
Nanoparticle-delivered COVID-19 vaccine candidate shows promise in preclinical studies
First COVID-19 COVAX vaccine doses administered in Africa
Assessing a compound's activity, not just its structure, could accelerate drug discovery
Arthritis drugs may reduce mortality and time in ICU for sickest COVID patients
Conferences & Events
Scientists urge for investment now in highly potent vaccines to prevent the next pandemic
CPhI Worldwide to return in 2021
Reuters Events' Cell & Gene Therapy USA
Total health: Build a better healthcare system
Don't fall for the 'next best action' trap
Locking down shape-shifting spike protein aids development of COVID-19 vaccine
COVID-19 vaccine innovation could dramatically speed up worldwide production
Regulatory Affairs
FDA issues Emergency Use Authorization for third COVID-19 vaccine
FDA Authorizes Monoclonal Antibodies for Treatment of COVID-19
EMA receives application for conditional marketing authorisation of COVID-19 Vaccine AstraZeneca
FDA takes additional action in fight against COVID-19 by issuing Emergency Use Authorization for second COVID-19 vaccine
Update on assessment of the BioNTech and Pfizer BNT162b2 vaccine marketing authorisation application
You are here:
Home
GlaxoSmithKline
Sanofi and GSK initiate new Phase 2 study of their adjuvanted recombinant protein-based COVID-19 vaccine candidate